mm-141
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2012 (NCT01733004)
Timeline
Indications
Mechanism of action
IGF1R inhibitor
ERBB3 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- mm-141
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02399137 | Phase 2 | May 1, 2015 | Merrimack Pharmaceuticals |
| NCT01733004 | Phase 1 | Nov 1, 2012 | Merrimack Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merrimack Pharmaceuticals | For profit | 2 | 2 | 2 | 2012 |
1 organizations
Page 1 / 1